# TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents

> **NCT00665847** · PHASE2 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 103 (actual)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** Etravirine (TMC125)
- **DRUG:** Optimized background regimen (OBR)

## Key facts

- **NCT ID:** NCT00665847
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2011-05
- **Final completion:** 2011-08
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2015-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00665847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00665847, "TMC125-TiDP35-C213: Safety and Antiviral Activity of Etravirine (TMC125) in Treatment-Experienced, HIV Infected Children and Adolescents". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT00665847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*